Qiagen Buys Cellestis For QuantiFeron “Pre-Molecular” Diagnostics

Qiagen plans to incorporate Cellestis’ QuantiFeron “pre-molecular” diagnostics technology into its own automated and mobile testing platforms after acquiring the firm for $355 million in a deal announced April 3.